Welcome to Medivizor!

You're browsing our sample library. Feel free to continue browsing. You can also sign up for free to receive medical information specific to your situation.

Posted by on Jun 5, 2019 in Leukemia | 0 comments

In a nutshell

This study aimed to investigate the outcomes of allogeneic stem cell transplant (allo-SCT) after treatment with inotuzumab ozogamicin (Besponsa) for patients with relapsed/unresponsive acute lymphoblastic leukemia (ALL)This study concluded that allo-SCT provided optimal long-term survival benefit for these patients.

Some background

Relapsed or unresponsive ALL is challenging to treat. Inotuzumab ozogamicin (InO) is a targeted therapy used for the treatment of these patients.  

Allo-SCT is a procedure in which a person receives blood-forming stem cells from a genetically similar, but not identical, donor. This is often a sister or brother but could also be an unrelated donor. Allo-SCT is often offered to patients with relapsed or unresponsive ALL. However, the outcomes of allo-SCT after treatment with InO in these patients are still under investigation. 

Methods & findings

This study involved 236 InO treated patients with relapsed or unresponsive ALL. 43% (101) proceeded to allo-SCT and were included in this analysis. 

The average post-transplant overall survival (OS; time from transplant to death from any cause) was 9.2 months. The 2-year survival probability was 41%. Compared to standard treatment, patients who received InO had a lower 2-year risk of relapse (45.7% with standard treatment vs 28.6% with InO).

In first-time allo-SCT patients, the average OS was 11.8 months. The 2-year survival probability was 46%. Some patients relapsed and needed more treatment before SCT. Patients that went directly to first-time HSCT upon remission had a  2-year survival probability of 51%.  

The bottom line

This study concluded that in patients with relapsed or unresponsive ALL, InO followed by allo-HSCT provided optimal long-term survival benefit for those with no previous allo-HSCT who went directly to transplant after remission. 

The fine print

This study included a small number of participants. Further studies are needed.

What’s next?

Published By :

Biology of blood and marrow transplantation: journal of the American Society for Blood and Marrow Transplantation

Date :

Apr 27, 2019

Original Title :

Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia.

click here to get personalized updates